Metformin and troglitazone in the treatment of female infertility associated with polycystic ovarian syndrome

Journal of the Nepal Medical Association

Volumn 48, Issue 176, 2009, Pages 335-339

  Sangraula, H ^a   Paudel, K R ^b   Sharma, M ^a  

^a BPKIHS   (Nepal)

^b KMC   (Nepal)

Author keywords

Infertility; Metformin; Ovary; Troglitazone

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; CHROMAN DERIVATIVE; METFORMIN; TROGLITAZONE;

ANOVULATION; FEMALE; FEMALE INFERTILITY; HUMAN; OVARY POLYCYSTIC DISEASE; REVIEW;

ANOVULATION; CHROMANS; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INFERTILITY, FEMALE; METFORMIN; POLYCYSTIC OVARY SYNDROME; THIAZOLIDINEDIONES;

EID: 79952277600     PISSN: 00282715     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (51)

1. Leo VD, Marca AL, Ditto A, Morgante G, et al. The Role of Metformin in FSH-Treated Women with PCOS. Fertil Steril. 2004;72(2):282-5.
2. Asuncion M, Calvo RM, San Millan JL, et al. A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain. J Clin Endocrinol Metab. 2000;85:2434-8.
3. Knochenhauer ES, Key TJ, Kahsar-Miller M, et al. Prevalence of the polycystic ovary syndrome in unselected black and white women of the southeastern United States: a prospective study. J Clin Endocrinol Metab. 1998;83:3078-82.
4. Franks S. Polycystic ovary syndrome. N Engl J Med. 1995;333:853-61.
5. Asuncion M, Calvo RM, San Millan JL, et al. A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain. J Clin Endocrinol Metab. 2000;85(24):34-8.
6. Sinha A, Atiomo W. The role of metformin in the treatment of infertile women with polycystic ovary syndrome. The obstetrician and gynaecologist 2004 [cited 2007 May 6]; 6:145-51. Available from: URL:http://www.rcog.org.uk/togonline
7. Jakubowicz DJ, Iuorno MJ, Jakubowicz S, et al. Effects of Metformin on Early Pregnancy Loss in the Polycystic Ovary Syndrome. J Clin Endocrinol Metab. 2002;87:524-9.
8. Carmina E, Koyama T, Chang L, et al. Does ethnicity influence the prevalence of adrenal hyperandrogenism and insulin resistance in polycystic ovary syndrome? Am J Obstet Gynecol. 1992;167:1807-12.
9. Dunaif A, Segal KR, Futterweit W, Dobrjansky A. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes. 1989;38:1165-74.
10. Malesh VB, Greenblatt RB. Isolation of dehydroepiandrosterone and 17 - hydroxy- pregnenolone from polycystic ovaries of the Stein-Leventhal syndrome. J Clin Endocrinol Metab. 1962;22:441-4.
11. Roy S, Mahesh VB, Greenblatt RB. Effect of dehydroepiandrosterone and 4-androstenedione on the reproductive organs of female rats: production of cystic changes in the ovary. Nature. 1962;196:2-6.
12. Lee MT, Anderson E, Lee GY. Changes in ovarian morphology and serum hormones in the rat after treatment with dehydroepiandrosterone. Anatomical Record. 1991;231:185-92.
13. Anderson E, Lee MT, Lee G. Cystogenesis of the ovarian antral follicle of the rat: ultrastructural changes and hormonal profile following the administration of dehydroepiandrosterone. Anatomical Record. 1992;234:359-82.
14. Henmi H, Endo T, Nagasawa K, et al. Lysyl oxidase and MMP-2 expression in dehydroepiandrosterone-induced polycystic ovary in rats. Biology of Reproduction. 2001;64:157-62.
15. Willis D, Mason H, Gilling-Smith C, Franks S. Modulation by insulin of follicle-stimulating hormone and luteinizing hormone actions in human granulosa cells of normal and polycystic ovaries. J Clin Endocrinol Metab. 1996;81(1):302-9.
16. Franks S, Gilling-Smith C, Watson H, Willis D. Insulin action in the normal and polycystic ovary. Endocrinol Metab Clin North Am. 1999;28(2):361-78.
17. Wu XK, Zhou SY, Liu JX, et al. Selective ovary resistance to insulin signaling in women with polycystic ovary syndrome. Fertil Steril. 2003;80(4):954-65.
18. Willis D, Franks S. Insulin action in human granulosa cells from normal and polycystic ovaries is mediated by the insulin receptor and not the type-I insulin-like growth factor receptor. J Clin Endocrinol Metab. 1995;80(12):3788-90.
19. Navarra P, Andreani CL, Lazzarin N, et al. Increased production and release of prostaglandin E2 by human granulosa cells from polycystic ovaries. Prostaglandins. 1996;52:187-97.
20. Wojtowicz-Praga S. Reversal of tumor-induced immunosuppression: a new approach to cancer therapy. J Immunother. 1997;20:165-77.
21. Franks S, Mason H, Willis D. Follicular dynamics in the poly-cystic ovary syndrome. Molecular Cellular Endocrinology. 2000;25:49-52.
22. Mendonca HC, Montenegro RM, Foss MC, et al. Positive correlation of serum leptin with estradiol levels in patients with polycystic ovary syndrome. Braz J Med Biol Res. 2004;37:729-36.
23. Doi SA, Al-Zaid M, Towers PA, et al. Irregular cycles and steroid hormones in polycystic ovary syndrome. Hum Reprod. 2005;20:2402-8.
24. Priddy AR, Killick SR. Eicosanoids and ovulation. Prostaglandins Leukot Essent Fatty Acids. 1993;49:827-43.
25. Kuroda E, Yamashita U. Mechanisms of enhanced macrophage-mediated prostaglandin E2 production and its suppressive role in Th1 activation in Th2-dominant BALB/c mice. J Immunol. 2003;15:757-64.
26. Lakier SL. Overtraining, excessive exercise, and altered immunity: is this a T helper-1 versus T helper-2 lymphocyte response? Sports and Medicine. 2003;33:347-64.
27. Yang L, Yamagata N, Yadav R, et al. Cancer-associated immunodeficiency and dendritic cell abnormalities mediated by the prostaglandin EP2 receptor. J Clin Investig. 2003;11:727-35.
28. Sander V, Luchetti CG, Solano ME, et al. Role of the N, N'- dimethylbiguanide metformin in the treatment of female prepuberal BALB/c mice hyperandrogenized with dehydroepiandrosterone. Reproduction. 2006;131:591-602.
29. Luchetti CG, Solano ME, Sander V, et al. Effects of dehydroepiandrosterone on ovarian cystogenesis and immune function. J Reprod Immunol. 2004;64:59-74.
30. Ivanov A, Romanovsky AA. Prostaglandin E2 as a mediator of fever: synthesis and catabolism. Frontiers in Bioscience. 2004;1:1977-93.
31. Sayin NC, Gucer F, Balkanli-Kaplan P, et al. Elevated serum TNF-alpha levels in normal-weight women with polycystic ovaries syndrome. J Reprod Med. 2003;48:165-217.
32. Peral B, San Millan JL, Castello R, et al. Comment: the methionine 196 arginine polymorphism in exon 6 of the TNF receptor 2 gene (TNFRSFIB) is associated with the polycystic ovary syndrome and hyperandrogenism. J Clin Endocrinol Metab. 2002;87:3977-83.
33. Spaczynski RZ, Arici A, Duleba AJ. Tumor necrosis factor-alpha stimulates proliferation of rat ovarian theca-interstitial cells. Biology of Reproduction. 1999;61:993-8.
34. Di Gregorio GB, Yao-Borengasser A, Rasouli N, et al. Expression of CD68 and macrophage chemoattractant protein-1 genes in human adipose and muscle tissues: association with cytokine expression, insulin resistance, and reduction by pioglitazone. Diabetes. 2005;54:2305-13.
35. Kiortsis DN, Filippatos TD, Elisaf MS. The effects of orlistat on metabolic parameters and other cardiovascular risk factors. Diabetes and Metabolism. 2005;31:15-22.
36. Homburg R, Armar NA, Eshel A, et al. Influence of serum luteinising hormone concentrations on ovulation, conception, and early pregnancy loss in polycystic ovary syndrome. BMJ. 1998;297:1024-6.
37. Regan L, Owen EJ, Jacobs HS. Hypersecretion of luteinising hormone, infertility and miscarriage. Lancet. 1990;336:1141-4.
38. Atiomo WU, Hilton D, Fox R, et al. Immunohistochemical detection of plasminogen activator inhibitor-1 in polycystic ovaries. Gynecol Endocrinol. 2000;14:162-8.
39. Tarlatzis R, Fauser B, Chang J, et al. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS).The Rotterdam ESHRE/ASRM-Sponsored PCOS consensus workshop group. Hum Reprod. 2004;19:41-7.
40. Musso C, Shawker T, Cochran E, et al. Clinical evidence that hyperinsulinaemia independent of gonadotropins stimulates ovarian growth. Clin Endocrinol (Oxf). 2005;63:73-8.
41. Vandermolen DT, Ratts VS, Evans WS, et al. Metformin increases the ovulation rate and pregnancy rate from clomiphene citrate in patients with polycystic ovary syndrome who are resistant to clomiphene citrate alone. Fertil and Steril. 2001;75:310-5.
42. Dominguez LJ, Sowers JR. Metabolic syndrome therapy: prevention of vascular injury by antidiabetic agents. Current Hypertension Reports. 2005;7:110-6.
43. Lord JM, Flight IH, Norman RJ. Insulin-sensitising drugs (metformin, troglitazone, rosiglitazone, pioglitazone, D-chiroinositol) for polycystic ovary syndrome. Cochrane Database System Reviews. 2003;3:CD0033053.
44. Mansfield R, Galea R, Brincat M, et al. Metformin has direct effects on human ovarian steroidogenesis. Fertil and Steril. 2003;79:956-62.
45. Stefanovic V, Antic S, Mitic-Zlatkovic M, Vlahovic P. Reversal of increased lymphocyte PC-1 activity in patients with type 2 diabetes treated with metformin. Diabetes and Metabolism Research Reviews. 1999;15:400-4.
46. Nestler JE, Jakubowicz DJ, Evans WS, Pasquali R. Effects of metformin on spontaneous and clomifene induced ovulation in the polycystic ovary syndrome. N Engl J Med. 1998;338:1876-80.
47. El-Biely MM, Habba M. The use of metformin to augment the induction of ovulation in obese infertile patients with polycystic ovary syndrome. Middle East Fertil Soc J. 2001;6:43-9.
48. Ng EH, Wat NM, Ho PC. Effects of metformin on ovulation rate, hormonal and metabolic profiles in women with clomifene-resistant polycystic ovaries: a randomised double-blinded placebo-controlled trial. Hum Reprod. 2001;16:1625-31.
49. Kocak M, Caliskan E, Simsir C, Haberal A. Metformin therapy improves ovulatory rates, cervical scores, and pregnancy rates in clomifene citrate resistant women with polycystic ovary syndrome. Fertil Steril. 2002;77:101-6.
50. Vandermolen DT, Ratts VS, Evans WS, et al. Metformin increases the ovulatory rate and pregnancy rate from clomifene citrate in patients with polycystic ovary syndrome who are resistant to clomifene citrate alone. Fertil Steril. 2001;75:310-5.
51. Lord JM, Flight IH, Norman RJ. Metformin in polycystic ovary syndrome: systematic review andmeta-analysis. BMJ. 2003;327:951-6.